Geode Capital Management, LLC Mersana Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,413,215 shares of MRSN stock, worth $5.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,413,215

Previous 2,493,423 3.22%

Holding current value

$5.36 Million

Previous $5.01 Million 9.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.23 - $2.25 $98,655 - $180,468	-80,208 Reduced 3.22%	2,413,215 $4.56 Million
Q2 2024 Aug 09, 2024	BUY	$2.0 - $4.45 $270,404 - $601,648	135,202 Added 5.73%	2,493,423 $5.01 Million
Q1 2024 May 13, 2024	BUY	$2.16 - $5.94 $131,943 - $362,844	61,085 Added 2.66%	2,358,221 $10.6 Million
Q4 2023 Feb 13, 2024	BUY	$1.11 - $2.34 $154,812 - $326,362	139,471 Added 6.46%	2,297,136 $5.33 Million
Q3 2023 Nov 13, 2023	BUY	$1.06 - $3.91 $161,101 - $594,253	151,983 Added 7.58%	2,157,665 $2.74 Million
Q2 2023 Aug 11, 2023	BUY	$3.08 - $9.55 $637,051 - $1.98 Million	206,835 Added 11.5%	2,005,682 $6.6 Million
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $365,508 - $641,466	91,377 Added 5.35%	1,798,847 $7.39 Million
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $324,598 - $451,564	57,451 Added 3.48%	1,707,470 $10 Million
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $361,505 - $624,632	78,079 Added 4.97%	1,650,019 $11.2 Million
Q2 2022 Aug 12, 2022	BUY	$2.84 - $5.0 $1.15 Million - $2.03 Million	405,133 Added 34.72%	1,571,940 $7.26 Million
Q1 2022 May 13, 2022	BUY	$3.74 - $6.63 $111,474 - $197,613	29,806 Added 2.62%	1,166,807 $4.66 Million
Q4 2021 Feb 11, 2022	BUY	$5.48 - $9.86 $398,209 - $716,486	72,666 Added 6.83%	1,137,001 $7.07 Million
Q3 2021 Nov 12, 2021	BUY	$8.56 - $14.47 $106,280 - $179,659	12,416 Added 1.18%	1,064,335 $10 Million
Q2 2021 Aug 13, 2021	BUY	$13.28 - $18.07 $1.25 Million - $1.7 Million	93,868 Added 9.8%	1,051,919 $14.3 Million
Q1 2021 May 12, 2021	BUY	$15.31 - $26.52 $1.51 Million - $2.62 Million	98,750 Added 11.49%	958,051 $15.5 Million
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $510,673 - $836,666	30,325 Added 3.66%	859,301 $22.9 Million
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $1.1 Million - $1.74 Million	67,724 Added 8.9%	828,976 $15.4 Million
Q2 2020 Aug 13, 2020	BUY	$5.24 - $23.4 $1.21 Million - $5.42 Million	231,464 Added 43.69%	761,252 $17.8 Million
Q1 2020 May 14, 2020	BUY	$4.41 - $9.28 $2,716 - $5,716	616 Added 0.12%	529,788 $3.09 Million
Q4 2019 Feb 13, 2020	BUY	$1.45 - $6.73 $64,902 - $301,234	44,760 Added 9.24%	529,172 $3.03 Million
Q3 2019 Nov 12, 2019	BUY	$1.54 - $4.2 $1,841 - $5,023	1,196 Added 0.25%	484,412 $765,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $436,051 - $726,752	113,555 Added 30.72%	483,216 $1.96 Million
Q1 2019 May 14, 2019	BUY	$3.51 - $7.3 $847,415 - $1.76 Million	241,429 Added 188.28%	369,661 $1.94 Million
Q4 2018 Feb 13, 2019	BUY	$3.45 - $9.72 $20,003 - $56,356	5,798 Added 4.74%	128,232 $523,000
Q3 2018 Nov 13, 2018	BUY	$10.0 - $19.02 $315,250 - $599,605	31,525 Added 34.68%	122,434 $1.22 Million
Q2 2018 Aug 14, 2018	BUY	$14.2 - $22.68 $66,626 - $106,414	4,692 Added 5.44%	90,909 $1.62 Million
Q1 2018 May 15, 2018	BUY	$13.56 - $18.48 $312,476 - $425,853	23,044 Added 36.48%	86,217 $1.36 Million
Q4 2017 Feb 13, 2018	BUY	$14.95 - $19.9 $87,023 - $115,837	5,821 Added 10.15%	63,173 $1.04 Million
Q3 2017 Nov 14, 2017	BUY	$14.8 - $18.06 $848,809 - $1.04 Million	57,352	57,352 $991,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Mersana Therapeutics, Inc. Transaction History